Neuronetics Expands NeuroStar® TMS Therapy Coverage
Neuronetics, Inc. (NASDAQ: STIM), renowned for its innovative medical technology, has made waves by expanding its NeuroStar Advanced Therapy coverage to adolescents aged 15 and older. This exciting development, recently announced, will provide much-needed support for young individuals battling depression.
TRICARE Coverage Enhancements
TRICARE, primarily covering active and retired military service members and their families, has updated its policy to include TMS coverage for teenagers. This proactive measure reflects a growing recognition of the mental health challenges that adolescents face today. The policy is effective immediately, representing a significant advancement in mental health care for families associated with the military.
Impact of Military Life on Mental Health
Military life can impose unique pressures, affecting not just service members but also their children. Geoffrey Grammer, Chief Medical Officer of Neuronetics and retired U.S. Army Colonel, emphasizes the importance of this policy change. The expansion allows the children of military personnel access to effective mental health treatments, providing vital support during challenging times.
The Importance of TMS in Treating Depression
With an alarming 4.3 million adolescents in the U.S. impacted by major depression, the need for effective treatments is more pressing than ever. Depression can hinder various aspects of a teenager's life, including academic performance and relationships. NeuroStar TMS therapy offers a safe and effective non-pharmaceutical treatment option. It's particularly important as it does not require prior medication failures, making it a first-choice option for treating these young patients.
Clinical Outcomes and Insurance Coverage
The FDA cleared NeuroStar TMS for adolescent patients back in 2024, and since then, its coverage has expanded to include various insurance providers. This includes major players like Evernorth Health Services, BlueCross BlueShield Health Care Service Corporation, and Humana, ensuring that more young people have access to this transformative treatment.
Neuronetics' Commitment to Mental Health
Not only is Neuronetics a pioneer in TMS therapy for adolescents, but it also boasts a dedicated health policy team that collaborates with providers and insurers. Their goal is to advocate and facilitate access to mental health treatments for all patients, especially the underrepresented youth demographic. This commitment showcases Neuronetics' dedication to enhancing the lives of those suffering from mental health disorders.
About Neuronetics and NeuroStar
Neuronetics operates several Greenbrook TMS Inc. centers throughout the United States, where they offer NeuroStar Advanced Therapy for various mental health disorders. Their treatments are backed by a wealth of clinical data, further solidifying their position as leaders in the neurohealth industry. They serve over 60,000 patients, delivering more than 2 million treatments to date.
Partnering for Better Solutions
As Neuronetics continues to innovate and expand its services, it remains focused on overcoming the barriers to effective mental healthcare. Their collaboration with insurers to provide coverage for TMS therapy exemplifies their philanthropic goal of making advanced healthcare accessible to all while respecting the sacrifices of military families.
Frequently Asked Questions
What is NeuroStar TMS Therapy?
NeuroStar TMS Therapy is a non-invasive treatment designed to alleviate symptoms of major depressive disorder using transcranial magnetic stimulation.
Who is eligible for the new TRICARE coverage?
The updated TRICARE policy now includes adolescents aged 15 and older who are beneficiaries of the TRICARE program.
How does TMS Therapy work?
TMS therapy involves using magnetic fields to stimulate nerve cells in the brain, which can improve mood and alleviate depressive symptoms.
Is NeuroStar TMS safe for adolescents?
Yes, NeuroStar TMS has been deemed safe and effective for treating adolescents aged 15-21 based on clinical studies.
What should families do to access TMS treatment?
Families should consult with their healthcare provider to determine if NeuroStar TMS therapy is appropriate and begin the coverage process through TRICARE.
